Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07441694 · ClinicalTrials.gov registry record · Phase 1
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
A Phase 1 study of Myeloproliferative Neoplasms, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 218
- Enrollment target
- 20
- Study locations
NCT07441694: Recruiting Phase 1 study of Myeloproliferative Neoplasms, sponsored by Incyte Corporation.
NCT07441694 is a Phase 1 study of Myeloproliferative Neoplasms that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 218 participants, above the 124-participant average among 8 other Myeloproliferative Neoplasms trials with a reported enrollment target (76% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07441694, a Phase 1 study of Myeloproliferative Neoplasms, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 218 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
Primary Outcome
Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.
Conditions Studied
Interventions
- DRUG INCA036978
- DRUG Standard disease-directed therapy
Study Locations (20)
California
- City of Hope-Lennar Foundation Cancer Center - Irvine
- Usc Norris Comprehensive Cancer Center - Los Angeles
- UCLA Medical Hematology & Oncology - Los Angeles
North Carolina
- University of North Carolina At Chapel Hill - Chapel Hill
- Levine Cancer Institute - Charlotte
- Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy - Durham
Florida
- University of Miami - Miami
- Moffitt Cancer Center - Tampa
New York
- Mount Sinai School of Medicine - New York
- Weill Cornell Medicine - New York
Ohio
- Cleveland Clinic - Cleveland
- Ohio State University - Columbus
Alabama
- University of Alabama At Birmingham - Birmingham
Connecticut
- Yale Cancer Center - New Haven
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2026-03-29 |
| Est. Completion | 2030-05-24 |
| Phase | Phase 1 |
What NCT07441694 shows while recruiting
NCT07441694 is an interventional study that assigns participants to a tested intervention. The registered 218 participants enrollment target is mid-sized for trials with a published cap, above the 124-participant average among 8 other Myeloproliferative Neoplasms trials with a reported enrollment target (76% higher).
The record links to 1 condition, with Myeloproliferative Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which INCA036978 is the first listed.
NCT07441694 names 20 study sites across 13 states, led by California, North Carolina, Florida.
Frequently Asked Questions
What is clinical trial NCT07441694 about?
NCT07441694 is a clinical study titled "Study of INCA036978 in Participants With Myeloproliferative Neoplasms". This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
What is the current status of trial NCT07441694?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 218 participants. The study started on 2026-03-29. Estimated completion is 2030-05-24.
What conditions does trial NCT07441694 study?
This clinical trial studies the following conditions: Myeloproliferative Neoplasms.
What interventions are being tested in trial NCT07441694?
The interventions under investigation include: INCA036978 (DRUG), Standard disease-directed therapy (DRUG).
Who is sponsoring clinical trial NCT07441694?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07441694 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloproliferative Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07441694's enrollment target sits among peer trials
218 3rd of 8 higher than 6 of 8 other Myeloproliferative Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myeloproliferative Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
RECRUITING · Phase 1
-
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
ACTIVE NOT RECRUITING · Phase 1
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04693858 · 218 participants · NA
Efficacy Trial of the CALM Intervention
- NCT05909202 · 218 participants · NA
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
- NCT06000761 · 218 participants · NA
Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit
- NCT06249126 · 218 participants · NA
Primary Subtalar Arthrodesis for Calcaneal Fractures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI